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A B S T R A C T   
Batch release testing for human and veterinary tetanus vaccines still relies heavily on methods that involve animals, particularly for potency testing. The quantity and 
quality of tetanus antigen present in these products is of utmost importance for product safety and clinical effect. Immunochemical methods that measure consistency 
of antigen content and quality, potentially as an indicator of potency, could be a better choice and negate the need for an in vivo potency test. These immunochemical 
methods require at least one well characterised monoclonal antibody (mAb) that is specific for the target antigen. In this paper we report the results of the 
comprehensive characterisation of a panel of mAbs against tetanus with a view to select antibodies that can be used for development of an in vitro potency 
immunoassay. We have assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody 
function was determined using an in-house cell-based neutralisation assay to support prior in vivo potency data that was available for some, but not all, of the 
antibodies. In addition, antibody affinity was measured, and epitope competition analysis was performed to identify pairs of antibodies that could be deployed in a 
sandwich immunoassay format. Not all characterisation tests provided evidence of “superiority” of one mAb over another, but together the results from all char-
acterisation studies allowed for selection of an antibody pair to be taken forward to assay development.   
1. Introduction 
This work is part of the VAC2VAC project, which is a public-private 
consortium of 22 partners funded by the Innovative Medicines Initiative 
2 (IMI2). The main objective for VAC2VAC [1] is to develop in vitro 
assays that will support regulatory acceptance of a consistency approach 
[2] and ultimately reduce the use of animals for batch testing as part of 
routine vaccine production in the future. 
A range of established model vaccines were selected for the VAC2-
VAC project based on the large proportion of the animals used for vac-
cine potency testing, the severity of discomfort in these tests or as 
models for complex or difficult to assay adjuvants. Established vaccine 
products are produced by traditional processes of inactivation or 
attenuation of the micro-organisms or their antigenic components (e.g. 
vaccines for rabies, pertussis, diphtheria, tetanus and other Clostridia) 
and may historically be less well defined than new generation vaccines, 
such as recombinant DNA products or sub-unit vaccines, for which 
consistency testing is already an accepted approach for quality control. 
Tetanus toxoid (TTxd) was selected as one of the target antigens as it is 
used widely for the immunisation of both humans and animals. Tetanus 
vaccine for human use, in combination vaccines containing other anti-
gens, forms part of the routine immunisation schedule for infants in 
many countries. Around 86% of infants globally received three vaccine 
doses, containing a tetanus component, in 2018 according to WHO 
Global Health Observatory data [3]. Tetanus vaccines are also an inte-
gral part of preventing disease in highly sensitive animal species. Hence, 
they are used routinely for immunisation of horses and all small rumi-
nants (sheep, goats, llamas and alpacas), and are also recommended for 
cattle to prevent bovine tetanus in areas of high risk. 
The potency of the tetanus vaccine is determined for each final lot (or 
final formulated bulk) as part of routine batch release procedures. 
Although the test methodology varies in different regulatory jurisdic-
tions, all potency tests for human and veterinary tetanus vaccines 
currently require the use of animals [4,5]. The high number of vaccine 
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batches produced, and the requirement to use animals for quality con-
trol testing, means that development of a non-animal potency test for 
tetanus vaccines could have a significant impact in terms of reducing 
animal use and enhancing test precision during product manufacturing 
and batch release. 
We have previously developed a capture ELISA method (using a 
monoclonal antibody for capture and a polyclonal antiserum for detec-
tion) for the quantification of tetanus antigen in combination vaccines 
and showed that this method could be applied to a range of different 
vaccines licensed for use in humans [6]. As part of the VAC2VAC project, 
we evaluated this capture antigen ELISA for the characterisation of 
tetanus vaccines for veterinary use, which have qualitative differences 
to human vaccines as they contain different adjuvants and additional 
antigens not licensed for human use [7]. The results suggested that the 
method could also be appropriate for use in a control strategy for vet-
erinary tetanus vaccines. However, the capture ELISA developed pre-
viously uses a polyclonal detection antibody making it more difficult to 
implement and validate the assay as part of a control strategy because of 
variability between different production batches and difficulties iden-
tifying specific antibodies in a polyclonal population that are targeting 
functionally relevant epitopes (i.e. epitopes to which neutralising anti-
bodies are directed). Our aim is therefore to improve the assay by using 
fully characterised monoclonal antibodies for both capture and detec-
tion of the target antigen. 
In this study we report the results of an extensive characterisation of 
a panel of four monoclonal antibodies against tetanus with a view to 
select antibodies that can be used for development of an immunoassay 
that can potentially serve as an in vitro potency assay for tetanus vaccine. 
To do this we have assessed binding of the antibodies to native antigen 
(toxin, TTxn), detoxified antigen (toxoid), adsorbed antigen and heat- 
altered antigen. Where possible, we have used representative antigen 
samples from two different human and four different veterinary vaccine 
manufacturers to assess mAb binding. Antibody function was deter-
mined using an in-house cell-based neutralisation assay. In addition, 
antibody affinity was measured, and epitope competition analysis was 
performed (using toxin) to identify pairs of antibodies that could be 
deployed in a sandwich immunoassay format. 
2. Materials and methods 
2.1. Monoclonal antibodies 
Four tetanus mAb samples were characterised in this study, which 
were raised in either rat or mouse, from three providers in the VAC2VAC 
consortium (Table 1). The mAbs were from different providers, so 
commercial ELISA kits were used to measure the IgG concentration in 
mouse (Mouse-IgG ELISA, Roche) or rat (Immunoglobulin G Rat Sim-
pleStep ELISA® Kit, abcam) to help standardise antibody concentrations 
in binding assays and facilitate comparisons (data not shown). 
2.2. Antigen samples 
2.2.1. Compliant samples 
Non-adsorbed tetanus toxoid (TTxd) and bulk adsorbed tetanus 
toxoid (Ad-TTxd) from two human vaccine manufacturers (coded HuA 
and HuB) and four different veterinary manufacturers (coded A-D) were 
used to assess binding of the mAbs to detoxified antigen. These samples 
were compliant with all quality requirements for manufacturing, and 
representative of TTxd used to produce batches that are efficacious in 
clinical or field studies. The TTxd samples from the human manufac-
turers and veterinary company D were labelled with a concentration in 
Lf/ml, whereas the concentration was unknown for samples from com-
panies A-C. For these samples an approximate Lf/ml value was obtained 
using an in-house capture ELISA [6] to allow suitable working dilutions 
to be calculated. Details of the TTxd samples are shown in Table 2. Two 
tetanus toxins (TTxn, from List Biologicals; product code #190B, and 
from HuA) were used to assess mAb binding to native toxin. 
2.2.2. Altered samples 
Non-adsorbed TTxd samples from the human manufacturers were 
deliberately altered by exposure to elevated temperature to determine 
the impact on mAb binding. Samples were diluted in 0.9% NaCl to a 
concentration representative of the final vaccine products (20 Lf/ml) 
and then incubated for 8 weeks at elevated temperatures of +37 ◦C and 
+45 ◦C, with control samples held at the normal storage temperature of 
+4 ◦C. 
2.3. Binding to non-adsorbed antigen (toxin and toxoid) 
Direct ELISAs were performed using plates coated overnight at +4 ◦C 
with 100 μl/well of TTxn diluted to 30 μg/ml, or TTxd diluted to 
approximately 2 Lf/ml (based on labelled values of Lf/ml for TTxds from 
human manufacturers and veterinary company D, and measured values 
for veterinary companies A-C) in carbonate buffer, except for the TTxd 
from company A. This had an unusually low measured Lf/ml value and 
was diluted instead by a magnitude that was comparable to the other 
veterinary manufacturers (to give an estimated coating concentration of 
~0.1 Lf/ml). Following coating, plates were washed (3x) by immersion 
in phosphate buffered saline containing 0.05% (vol/vol) Tween 20 
(PBST), then blocked with 150 μl/well of PBST containing 2.5% (wt/vol) 
dried skimmed milk powder (PBSTM) for 1 h at +37 ◦C. Following a 
second wash in PBST, serial three-fold dilutions of the mAb samples in 
PBSTM were prepared in the plate (final volume 100 μl) from a starting 
concentration of 1–10 μg/ml, and the plates were incubated at +37 ◦C 
for 2 h. After further washing, bound mAb was detected using 100 μl/ 
well of the relevant HRP-conjugated IgG diluted 1/2000 in PBSTM 
(rabbit anti-rat for mAb TT010 and rabbit anti-mouse for the other 
mAbs). After a further incubation of 1 h at +37 ◦C and a final wash, 100 
μl/well of substrate solution containing 0.5 mg/ml ABTS and 0.008% 
hydrogen peroxide in 0.05 M citric acid buffer was added. The reaction 
was allowed to develop at room temperature for up to 30 min and the 
optical density was then measured at 405 nm (Molecular Devices, 
Table 1 
Overview of tetanus mAbs characterised in this study.  
Reagent Provider Species mAb ID 
NIBSC Rat TT010 
Sanofi Pasteur Mouse 18E11.3.4 
Sanofi Pasteur Mouse 8E1-1H1.2.1 
GSK Mouse TT1  
Table 2 
Non-adsorbed (non-adjuvanted) and adsorbed tetanus toxoid samples used for 









HuA TTxd non- 
adsorbed 
2500 N/A N/A 
HuB TTxd non- 
adsorbed 
4600 N/A N/A 
Veterinary A TTxd non- 
adjuvanted 
10a N/A N/A 
Veterinary B TTxd non- 
adjuvanted 
160a N/A N/A 
Veterinary C TTxd non- 
adjuvanted 
1400a N/A N/A 
Veterinary D TTxd non- 
adjuvanted 
425 N/A N/A 
HuA TTxd adsorbed 300 Aluminium 
phosphate 
1.38 
HuB TTxd adsorbed 27 Aluminium 
hydroxide 
1.00  
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Wokingham, UK). 
2.4. Binding to adsorbed antigen 
A modified version of the Direct Alhydrogel Formulation Immuno-
assay (DAFIA), established by Zhu et al. and Westdijk et al., was per-
formed to assess binding of the mAbs to Ad-TTxd [8,9]. The assay was 
performed as described previously using a colorimetric readout with an 
HRP-labelled secondary antibody, instead of a fluorometric readout. 
Briefly, Ad-TTxd was diluted to 1 Lf/ml in PBST containing 5% BSA 
(sample buffer, SB) and titrated using two-fold dilutions in the wells of a 
96 well plate (final volume 100 μl). The concentration of aluminium was 
kept constant by performing the titration in the related aluminium 
adjuvant diluted in SB. An adjuvant-only control was also included in 
the plate. Plates were centrifuged at 1000 g for 4 min and the super-
natant was gently removed using a pipette. Plates were washed (3x) by 
adding 200 μl/well of PBST containing 0.2% BSA, centrifuging and 
removing the supernatant as before. Following washing plates were 
blocked with 200 μl/well SB at room temperature with agitation for 1.5 
h. Plates were centrifuged and washed as described previously and mAb 
diluted to 1 μg/ml in SB (100 μl/well) was added for a further 1 h at 
room temperature with agitation. Following another centrifuge and 
wash step, bound mAb was detected using 100 μl/well of the relevant 
HRP-conjugated IgG diluted 1/2000 in SB (rabbit anti-rat for mAb 
TT010 and rabbit anti-mouse for the other mAbs). After a further in-
cubation of 1 h at room temperature with agitation and a final wash step, 
100 μl/well of TMB substrate was added and the plates were incubated 
in the dark for 5 min for the colour to develop. The reaction was stopped 
by the addition of an equal volume of 1 M H2SO4. To read the plates, 
100 μl of the supernatant from each well was transferred to a clean flat 
bottom plate and the absorbance was measured at 450 nm. 
2.5. Biosensor analysis 
2.5.1. Calibration free concentration analysis (CFCA) 
The active concentration of the mAbs for affinity measurements was 
determined on the Biacore system (Biacore T200, GE Healthcare, US). 
Briefly, a goat anti-mouse IgG Fc-specific antibody (Thermo Scientific) 
or a goat anti-rat antibody (Southern Biotech) was immobilised onto a 
CM5-sensorchip with a target level of 10,000 RU by primary amine 
coupling. A second flow cell which had been treated chemically without 
any anti-serum was used as the reference cell for determining non- 
specific binding. The mAbs were diluted to 0.5–2 μg/ml (based on IgG 
measurements) in HBS-P buffer, containing 0.1 M HEPES, 1.5 M NaCl 
and 0.5% v/v Surfactant P20 (GE Healthcare, US) and injected during 
36s at two different flow rates (5 and 100 μl/min). The sensor chip was 
regenerated with 10 mM glycine-HCl, pH 1.5. The active concentration 
was calculated from the slope of the binding curve (assuming a 1:1 
interaction model and using the molecular mass of 150 kDa for the 
antibody). 
2.5.2. Affinity measurements 
Affinity was determined using a protein G sensorchip. The mAbs 
were injected over the active flow cell resulting in a specific response of 
Fig. 1. mAb binding to tetanus toxin (TTxn). Data shows representative results from one of two independent assays for (A) Mouse mAbs binding to HuA TTxn; (B) 
Rat mAb binding to HuA TTxn; (C) Mouse mAbs binding to LIST TTxn; (D) Rat mAb binding LIST TTxn. 
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10–20 RU. TTxn (produced by Intravacc) was diluted to concentrations 
of 0.6, 1.3, 2.5, 5.0 and 10 μg/ml and injected in a single cycle for 3 min 
per concentration (flow rate 30 μl/min). The dissociation time was 30 
min after the injection of the highest concentration of TTxn. The kinetics 
were determined by direct curve fitting of the sensorgram to a 1:1 model 
interaction. 
2.5.3. Epitope competition analysis 
Epitope competition was performed using biosensor analysis with a 
CM5-sensorchip coupled to the relevant anti-mouse or anti-rat Fc-spe-
cific antibody (target level of 3500 RU) as described above. Subse-
quently, one of the mAbs was captured by the relevant immobilised 
antibody resulting in a response of 100–400 RU. Blocking was per-
formed using a non-specific monoclonal antibody (ImmunoPure Mouse 
IgG, Whole Molecule, Thermo Fisher Scientific, US). TTxn (50 μg/mL) 
was then injected until a plateau level was obtained (typically in 2 min 
at a flow rate of 30 μl/min). The binding of a second monoclonal anti-
body was analysed after 2 min (flow rate 10 μl/min). 
2.6. Neutralising ability 
The ability of the mAbs to neutralise TTxn was determined using an 
in-house cell-based assay. This assay is not yet published and is under-
going qualification in our laboratory, and is based on an assay developed 
for detection of Botulinum Toxin type B [10]. For this assay, a SiMa cell 
line that had been engineered to stably express luciferase-linked VAMP2 
protein (the target of TTxn) is used (NanoLuc-VAMP2 SiMa cells, engi-
neered by University of Sheffield). The assay is based on the principle 
that tetanus toxin exercises its proteolytic effect on the 
luciferase-VAMP-2 protein, leaving an exposed epitope that is 
recognised by a specific cleavage site antibody. The degree of proteolytic 
cleavage of VAMP-2 is a measure of the activity of tetanus toxin. The 
cleavage site antibody can be used to capture the cleaved VAMP-2 
protein with detection based on the fluorescent luciferase reporter 
protein. If a tetanus monoclonal antibody has neutralising activity, the 
amount of VAMP-2 cleavage will be reduced and the fluorescent signal 
will be reduced. NanoLuc VAMP2 cells were cultured in RPMI medium 
containing 10% foetal calf serum (FCS) and 5% penicillin/streptomycin 
(all cell culture reagents obtained from Life Technologies, unless 
otherwise stated) and passaged once weekly. Cells were differentiated in 
Neurobasal A Medium containing 1% Glutamax, 2% B27, 1% HEPES, 
1% MEM non-essential amino acids and 10 μM retinoic acid (R2625, 
Sigma), for 72 h. Cells were seeded at a density of 1 × 105 cells/well in 
48-well plates precoated with 10 μg/ml laminin (Sigma). Cells were 
treated for 72 h with 500 μl/well TTxn (190B, List Biologicals) alone or 
with TTxn that had been pre-incubated for 1 h with the mAbs diluted 
1/1000 (final concentration of TTxn 1.2 nM). TTxn that had been 
pre-incubated with a polyclonal tetanus antitoxin (NIBSC 66/021) 
diluted to 0.01 IU/ml was included as a positive control. Cells were 
detached using cell scrapers in 100 μl/well PBS containing 0.5% 
Triton-X100 and 1x SigmaFast protease inhibitor (Sigma). Cell lysates 
were incubated for 20 min on ice with frequent vortexing, followed by 
centrifugation at 14,000 rpm at +4 ◦C for 15 min. The supernatants were 
removed from storage at −20 ◦C prior to the luciferase assay. Lysates 
were tested for cleaved VAMP-2 using a one-step luciferase assay. 
Briefly; protein A 96-well plates (Thermo) were coated overnight at 
+4 ◦C with a VAMP2 cleavage site-specific antibody (rabbit polyclonal 
anti-CQ8, in-house) diluted 1:100 in PBS (50 μl/well). Plates were 
washed with PBST for 5 min on a plate shaker at 600 rpm (3x), and then 
blocked with PBS containing 1% (wt/vol) BSA for 1 h at room 
Fig. 2. mAb binding to non-adsorbed detoxified antigen (TTxd) from human vaccine manufacturers HuA and HuB. Data shows representative results from 
one of two independent assays for (A) Mouse mAbs binding to TTxd from HuA; (B) Rat mAb binding to TTxd from HuA; (C) Mouse mAbs binding to TTxd from HuB; 
(D) Rat mAb binding to TTxd from HuB. 
R. Riches-Duit et al.                                                                                                                                                                                                                            
Biologicals 71 (2021) 31–41
35
Fig. 3. mAb binding to non-adjuvanted detoxified antigen (TTxd) from veterinary vaccine manufacturers A, B, C and D. Data shows representative results 
from one of two independent assays for (A) Mouse mAbs binding to TTxd from veterinary company A; (B) Rat mAb binding to TTxd from veterinary company A; (C) 
Mouse mAbs binding to TTxd from veterinary company B; (D) Rat mAb binding to TTxd from veterinary company B; (E) Mouse mAbs binding to TTxd from vet-
erinary company C; (F) Rat mAb binding to TTxd from veterinary company C; (G) Mouse mAbs binding to TTxd from veterinary company D; (H) Rat mAb binding to 
TTxd from veterinary company D. 
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temperature with shaking. Following a second wash, cell lysates diluted 
1/4 in PBS were added (50 μl/well) and plates were incubated for a 
further 90 min at room temperature with shaking. Following a final 
wash, NanoGlo luciferase substrate (Promega) was diluted to 4% in PBS 
and added to wells (50 μl/well) for 5 min in the dark. Luminescence was 
measured using a SpectraMax M5 plate reader (Molecular Devices). 
3. Results 
3.1. Binding to TTxn and non-adsorbed TTxd 
At a coating concentration of 30 μg/ml of TTxn, all of the mAbs 
produced good binding curves, as shown in Fig. 1. The dose response 
curve for mAb TT010 is shown separately to the other mAbs because a 
different conjugate antibody (anti-rat) had to be used for detection of 
this sample. 
Binding was observed for all mAbs to TTxd from the two human 
manufacturers (Fig. 2) and to TTxd from three of the four veterinary 
manufacturers B, C and D, although binding to toxoid from manufac-
turer B was notably lower compared to other antigen samples (Fig. 3). 
None of the mouse mAbs were able to bind TTxd from manufacturer A 
and low binding was observed for the rat monoclonal antibody against 
this toxoid sample. 
3.2. Binding to adsorbed TTxd 
A direct alhydrogel method was used to assess binding of mAbs to 
Ad-TTxd samples in the presence of aluminium adjuvant. Representative 
vaccine samples from the two human manufacturers were used. All of 
the mAbs were able to bind to adsorbed TTxd from both manufacturers 
in the range of 0.015–1 Lf/ml but we observed high background and 
non-specific binding with mAb 18E11.3.4 (Fig. 4). 
3.3. Binding to heat altered TTxd 
The mAbs were tested to determine whether they could detect 
antigenic changes in non-adsorbed toxoid that had been altered by heat 
treatment. Representative toxoid samples from the human vaccine 
manufacturers were used for this analysis. The mAb binding curves to 
each of the samples at the 8-week time-point is shown in Fig. 5 (HuA 
TTxd) and Fig. 6 (HuB TTxd). There was no difference in mAb binding to 
TTxd diluted and incubated +4 ◦C compared to the same toxoid that had 
been diluted fresh on the day of the assay (for both HuA and HuB TTxds). 
Temperature induced changes in the TTxd from HuB were detected to 
the greatest extent by mAb 8E1-1H1.2.1 (as indicated by a downwards 
shift of the curve with samples incubated at +37 and + 45), followed by 
18E11.3.4 and TT1. The changes were detected the least by mAb TT010. 
The changes in TTxd from HuA were not as pronounced, and only small 
Fig. 4. mAb binding to adsorbed TTxd (Ad-TTxd) from human vaccine manufacturers HuA and HuB. Data shows representative results from one of two 
independent assays for (A) Mouse mAbs binding to Ad-TTxd from HuA; (B) Rat mAb binding to Ad-TTxd from HuA; (C) Mouse mAbs binding to Ad-TTxd from HuB; 
(D) Rat mAb binding to Ad-TTxd from HuB. Adsorbed antigen samples were titrated in a fixed adjuvant concentration and detected using a single concentration of 
mAb. Data are the average OD values from duplicate wells (±SEM). In (A) and (B), the OD value from control wells containing adjuvant, conjugate and substrate only 
(n = 4) is shown by a dashed grey line. In (C) and (D), the control well OD value for each mAb containing no Ad-TTxd (n = 2) is shown by a dotted line (green = mAb 
8E1-1H1.2.1; blue = mAb 18E11.3.4; red = mAb TT1 and black = mAb TT010). (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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differences were observed with mAbs 8E1-1H1.2.1, 18E11.3.4 and TT1, 
and only for the TTxd sample that had been incubated at the highest 
temperature. 
3.4. Affinity measurements and epitope competition 
First the active concentration was determined to select a suitable 
antibody dilution for the kinetic assay (not shown). Kinetic analysis was 
done using single cycle analysis, whereby each TTxn concentration was 
injected in one cycle and the protein G sensorchip was regenerated at the 
end. The sensorgrams obtained with each mAb are shown in Fig. 7. 
Results from the subsequent kinetic analysis are shown in Table 3, ar-
ranged in order of decreasing affinity for TTxn (the lower the KD value, 
the higher the affinity of the antibody). Both TT010 and 8E1-1H1.2.1 
have dissociation constants (KD) in the low nanomolar to picomolar 
range suggesting that both these mAbs have very high affinity for TTxn. 
For the epitope competition, TTxn was captured by a first mAb, and 
binding of a second mAb was then measured. Additional binding is ex-
pected to be observed on the sensorgram if the second mAb binds to a 
different epitope. Results are summarised in Table 4 and suggest that the 
four mAbs are all directed against different epitopes. 
3.5. Tetanus toxin neutralisation 
An in-house cell-based toxin neutralisation test was used to provide 
an indication of mAb function. The mAb samples, and a polyclonal 
positive control antitoxin, were pre-incubated with TTxn for 1 h before 
adding to cells. The polyclonal tetanus antitoxin (66/021) showed 
complete neutralisation of TTxn activity (as evidenced by a complete 
reversal of toxin-induced luminescence signal). Strong neutralising ac-
tivity was observed for mAb TT010 and partial neutralisation of toxin 
activity was seen with mAbs TT1 and 8E1-1H1.2.1. One of the mAbs, 
18E11.3.4, did not show any evidence of toxin neutralisation (Fig. 8). 
4. Discussion 
Immunoassays are used routinely in the quality control of many 
vaccines and in some cases have been specifically developed as alter-
natives to in vivo potency tests [4,11–18]. 
Immunity to tetanus is antibody mediated [19] so an approach to 
potency testing of tetanus vaccines that relies on the use of specific, 
functional antibodies targeting protective epitopes (i.e. those epitopes 
inducing formation of toxin-neutralising antibodies) is clinically rele-
vant. The use of hyperimmune serum to prevent the disease if the patient 
is not vaccinated also highlights the relevance of using an immunoassay 
with a neutralising mAb for a tetanus containing vaccine. 
Immunochemical methods that measure consistency of tetanus an-
tigen content and quality in vaccine products could potentially negate 
the need for an in vivo potency test, while at the same time increasing 
precision. Well characterised antibodies are essential for the develop-
ment of such assays, and where the assay is intended to serve as a po-
tency test, the antibody used should be of high affinity and should target 
an epitope(s) that is relevant for protection and is stability indicating 
[20–22]. We report here the thorough characterisation of a panel of 
existing tetanus mAbs with a view to selection of a pair of antibodies that 
can be used for development of a replacement in vitro tetanus vaccine 
potency assay. 
There was very little to distinguish the mAbs in terms of binding to 
native antigen (TTxn), or to non-adsorbed detoxified antigen (TTxd). 
This was the case whether binding to antigen was good (as was the case 
with most toxoid samples) or poor (as was the case with one toxoid in 
particular). The reason for poor binding to non-adsorbed toxoid from 
Fig. 5. mAb binding to non-adsorbed antigen (TTxd, HuA) exposed to elevated temperature for 8 weeks. Freshly diluted TTxd and TTxd samples that were 
incubated at +4, +37 or +45 ◦C for 8 weeks were titrated in the same assay. Data shown is the average OD value from duplicate wells (±SEM). 
R. Riches-Duit et al.                                                                                                                                                                                                                            
Biologicals 71 (2021) 31–41
38
veterinary manufacturer A is unclear but may be related to the direct 
ELISA format used for the binding experiments. The lower coating 
concentration used for this toxoid can also not be ruled out, however we 
have shown previously that one of the mAbs (a poor binder in this ELISA 
format) can function as a capture antibody for the tetanus toxoid from 
this manufacturer when the sample is tested in a sandwich ELISA format 
at the same concentration used for coating plates [7]. Preliminary data 
from sandwich ELISA assays using two of the four tetanus mAbs from 
this current study also show that the tetanus toxoid from this manu-
facturer can be reliably detected (unpublished observations). This sug-
gests that it is the direct ELISA format causing the poor binding observed 
for TTxd from manufacturer A. Direct coating of protein onto an ELISA 
plate may induce conformational changes that could reduce epitope 
availability [23–25], however this is an unlikely explanation for the 
results we observe here since all four mAbs, which target different epi-
topes, are poor binders. More likely is binding of non-toxin proteins in 
the toxoid sample that reduce the amount of target antigen bound to the 
plate and therefore reduce sensitivity. The ultimate aim is to develop a 
capture ELISA assay which will overcome any issues related to purity of 
toxoid or vaccine samples. 
For development of an in vitro potency assay, the test needs to be 
suitable for use with the drug product, i.e. the final vaccine. Many 
tetanus vaccines, whether for human or veterinary use, are formulated 
using an aluminium adjuvant, the presence of which may interfere with 
binding of antibody to the target antigen [7,8,26–28]. To assess binding 
of mAbs in the presence of adjuvant, we used a modified version of the 
Direct Alhydrogel Formulation Immunoassay (DAFIA) [8,9] where 
adsorbed antigen samples are titrated in a fixed concentration of adju-
vant. The principle of the assay is similar to an ELISA except that TTxd 
adsorbed to aluminium adjuvant is pelleted by centrifugation in wells of 
an ELISA plate (rather than being directly bound to the surface of the 
plate as in a traditional ELISA). The assay response was quite variable, 
mainly due to the difficulties in removing all of the reagent/wash buffer 
consistently from the adjuvant pellet during the wash steps but allowed 
us to identify low or high binders to the adsorbed antigen. All of the 
mAbs were able to bind to Ad-TTxd, however a high background was 
obtained with mAb 18E11.3.4 caused by non-specific binding of the 
mAb to the adjuvant. Although we only assessed non-specific binding of 
the antibodies to one of the human manufacturer vaccines containing an 
aluminium adjuvant, the significant non-specific binding observed 
makes mAb 18E11.3.4 unsuitable for taking forward into development 
of an immunoassay for measuring adsorbed tetanus antigen. 
To provide an indication of whether one or more of these antibodies 
is sensitive to changes in the antigen that are relevant for quality 
assessment, we deliberately altered non-adsorbed TTxd samples by 
exposure to heat. Two of the antibodies (8E1-1H1.2.1 and TT1) were 
sensitive to heat-induced changes in TTxd from HuA, but only at the 
highest storage temperature. More pronounced changes were observed 
with the TTxd from HuB and mAb 8E1-1H1.2.1 was most able to detect 
heat induced antigenic changes, with mAb TT010 being least sensitive. 
The altered sample study was performed using temperatures no higher 
than +45 ◦C with the aim of producing changes in the toxoid that would 
allow discrimination between the monoclonal antibodies in terms of 
their ability to recognise any alteration in the toxoid. The extent to 
which binding of each antibody was affected by heat-exposure of the 
toxoid may be related to the nature of the epitope to which they are 
directed, although we have not yet determined whether these antibodies 
recognise linear or conformational epitopes. Epitope mapping is the 
subject of ongoing work using cross-linking mass spectrometry. 
In vivo data on neutralising activity of the tetanus mAbs was avail-
able for some, but not all antibodies prior to initiating this work. 
Therefore, we assessed antibody function using an in-house cell-based 
Fig. 6. mAb binding to non-adsorbed antigen (TTxd, HuB) exposed to elevated temperature for 8 weeks. Freshly diluted TTxd and TTxd samples that were 
incubated at +4, +37 or +45 ◦C for 8 weeks were titrated in the same assay. Data shown is the average OD value from duplicate wells (±SEM). 
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assay. This assay allows detection of all steps of tetanus toxin action 
(binding to the cell surface, endocytosis, translocation of the toxin light 
chain and enzymatic cleavage of VAMP-2) using a luminescent enzy-
matic reaction. The assay is based on the principle that toxin-induced 
cleavage of VAMP-2 protein can be detected using a specific neo- 
epitope antibody. The assay used is based on an assay developed for 
Botulinum toxin type B, which shares the same intracellular target as 
tetanus toxin [10]. Three of the four mAbs were able to partially prevent 
the toxin-mediated cleavage of VAMP-2, with TT010 showing near 
complete neutralisation – bettered only by the polyclonal antitoxin 
positive control. Antibody 8E1-1H1.2.1 showed partial neutralisation 
but mAb 18E11.3.4 did not show any reduction of toxin effect in this 
assay model. This compared well with available (unpublished) data 
from mouse bioassays where 18E11.3.4 did not provide any protection 
and 8E1-1H1.2.1 did protect mice but only at the highest dose used (not 
shown), and where TT010 has a reported in vivo neutralising potency of 
13–33 IU/μg IgG [29]. Neutralisation data was not available for TT1 but 
the results obtained in the cell-based assay suggest that this mAb does 
have moderate toxin-neutralising ability. Two of the mAbs, TT010 and 
8E1-1H1.2.1, had affinities for tetanus toxin in the nano- or 
sub-nanomolar range and epitope competition studies showed that the 
mAbs were all directed against different epitopes, and therefore poten-
tially any combination would be suitable for use in the development of a 
sandwich immunoassay. The recognition of distinct epitopes by these 
monoclonal antibodies together with the evidence suggesting three of 
them have neutralising activity is consistent with previous studies that 
suggest there are multiple distinct epitopes on tetanus toxin to which 
neutralising antibodies may be directed [30,31]. 
Based on all these characterisation results, mAbs TT010 and 8E1- 
1H1.2.1 are the preferred pair to take forward to assay development. 
TT010 has the best neutralising ability and the highest affinity for TTxn. 
8E1-1H1.2.1 has a similar high affinity for TTxn and was also the best at 
being able to detect heat induced antigenic changes in non-adsorbed 
TTxd. The two selected mAbs are different species which avoids the 
need to biotinylate one of the antibodies in a sandwich ELISA. The 
development of the ELISA, using these two antibodies, is now underway 
and will assess the ability of this mAb pair to detect antigenic changes 
that are indicative of vaccine quality and stability for a wide range of 
Fig. 7. mAb-antigen interactions using the single cycle kinetic assay. Representative sensorgrams for (A) TT010, (B) 8E1-1H1.2.1, (C) 18E11.3.4 and (D) TT1 
are shown. The red arrow indicates where the dissociation starts after binding of TTxn in increasing concentrations. Response units are displayed on the y-axis and 
seconds are displayed on the x-axis of each graph. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.) 
Table 3 
Affinity of the tetanus mAbs for tetanus toxin.  






constant (KD, M) 
1 TT010 3.27E+05 3.12E-04 9.53E-10 
2 8E1- 
1H1.2.1 
3.63E+05 7.14E-04 1.97E-09 
3 18E11.3.4 2.64E+05 8.25E-03 3.13E-08 
4 TT1 3.75E+04 1.18E-03 3.16E-08  
Table 4 
Epitope competition for the tetanus mAbs.   
Second mAb 
First mAb  TT010 8E1-1H1.2.1 18E11.3.4 TT1 
TT010 - þ þ þ
8E1-1H1.2.1 þ - þ þ
18E11.3.4 þ þ - þ
TT1 þ þ þ -  
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tetanus vaccines from both human and veterinary manufacturers. 
The extensive characterisation of the monoclonal antibodies per-
formed in this study, including affinity, functional activity and recog-
nition of heat-altered antigen, provides a platform of evidence to 
support their use in development of a quantitative immunoassay that, 
subject to appropriate validation and regulatory approval, can be 
implemented as part of a control strategy for tetanus vaccines, poten-
tially as a substitute for in vivo potency. The antibodies characterised 
here recognise tetanus toxoid from multiple sources and three of the 
antibodies appear to be suitable for use with final lot vaccine (i.e. in the 
presence of adjuvant). An immunoassay developed using these anti-
bodies should therefore have wide applicability across a range of tetanus 
vaccines. Our aim is to use an antibody pair where, in addition to the 
recognition of multiple tetanus toxoids, including adjuvanted toxoid, the 
detection antibody recognises a functional epitope and is sensitive to 
heat-altered antigen. Further antigen stresses will be explored using an 
antibody pair to determine the extent to which a monoclonal antibody 
immunoassay is stability indicating. The possibility to produce recom-
binant versions of the selected antibodies will also be explored to ensure 
sustainability of critical reagents. 
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